NVO vs. PCVX: Novo Nordisk vs. Vaxcyte Stock Comparison

Company Profile

Novo Nordisk (NVO) and Vaxcyte (PCVX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NVO is classified in Pharmaceuticals while PCVX is classified in Biotechnology.

Novo Nordisk (NVO) has more than two decades of public-market history since April 30, 1981, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Vaxcyte (PCVX) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Novo Nordisk (NVO) reports 58.38%, ranking against industry peers normally.

Novo Nordisk (NVO) at 33.92% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

Novo Nordisk (NVO) at 40.05% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Novo Nordisk (NVO) reports revenue growth of 6.43%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Only one side can be read here: Novo Nordisk (NVO) reports EPS growth of 1.77%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Novo Nordisk (NVO) at 0.85 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVO.

Both Novo Nordisk (NVO) at 0.62 and Vaxcyte (PCVX) at 0.09 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Vaxcyte (PCVX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.

Vaxcyte (PCVX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Novo Nordisk (NVO) trades at 10.18 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

A sales-based read is only available for Novo Nordisk (NVO), whose P/S ratio of 0.53 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

On P/B ratio, both Novo Nordisk (NVO) at 5.43 and Vaxcyte (PCVX) at 3.83 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics